UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000062144
Receipt number R000071065
Scientific Title Study on the Effects of Continued Consumption of the Test Food on the Gut Microbiota - Single Arm Open Label Trial -
Date of disclosure of the study information 2026/07/14
Last modified on 2026/07/01 13:45:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on the Effects of Continued Consumption of the Test Food on the Gut Microbiota

Acronym

A study on the Effects of Continued Consumption of the Test Food on the Gut Microbiota

Scientific Title

Study on the Effects of Continued Consumption of the Test Food on the Gut Microbiota
- Single Arm Open Label Trial -

Scientific Title:Acronym

Study on the Effects of Continued Consumption of the Test Food on the Gut Microbiota
- Single Arm Open Label Trial -

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of 8 weeks of continuous consumption of the test food on the gut microbiota in men and women aged 20 to under 65 years.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Short-chain fatty acids

Key secondary outcomes

Gut microbiota composition,Bowel movement assessment


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Take 3 sachets of the test food per day (15 mL per sachet).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1.Aged 20 years or older and under 65 at the time of informed consent
2.Japanese men or women
3.Able to enter electronic diaries via smartphone or PC
4.Individuals who have received a thorough explanation of the study, fully understand its purpose and procedures, voluntarily wish to participate, and provide written informed consent

Key exclusion criteria

1.Currently receiving outpatient treatment or medication (including Kampo) for any disease (as-needed use permitted)
2.Under dietary or exercise therapy supervised by a physician
3.Current or past history of serious disease
4.Used medications affecting the study (e.g., antibiotics, probiotics, laxatives) within 1 month before consent, or plans to use during the study
5.Planned endoscopy, barium examination, H. pylori eradication, or tooth extraction during the study
6.History of gastrointestinal diseases or surgeries affecting digestion/absorption (excluding appendectomy or hemorrhoid surgery)
7.Currently taking quasi-drugs, specified health foods, health foods, or supplements 3 or more days per week (those taking <=2 days/week must maintain same frequency/amount; starting new intake is prohibited)
8.Current or past history of drug or food allergies
9.Habitual excessive alcohol consumption (>=40g pure alcohol/day)
10.Habitual excessive smoking (>=21 cigarettes/day)
11.Shift workers with night shifts
12.Plans to significantly change lifestyle (diet, sleep, exercise, etc.) during the study
13.Plans for overseas travel during the study
14.Pregnant, breastfeeding, or planning pregnancy during the study
15.Participated in another clinical study within 1 month before consent, currently participating, or planning to participate during the study
16.Deemed unsuitable for participation by the principal investigator

Target sample size

5


Research contact person

Name of lead principal investigator

1st name Kisato
Middle name
Last name Kusano

Organization

AUREO Co. Ltd.

Division name

Tokyo headquarters

Zip code

105-0014

Address

2-14-5 Shiba, Minato-ku, Tokyo 105-0014, Japan

TEL

03-6634-7853

Email

kusano-kisato@aureo.co.jp


Public contact

Name of contact person

1st name Yoshitada
Middle name
Last name Hira

Organization

IMEQRD Co., Ltd.

Division name

Planning and Sales Department

Zip code

104-0061

Address

6-2-1 Ginza, Chuo-ku, Tokyo, Japan

TEL

03-6704-5968

Homepage URL


Email

clinical-trial@imeqrd.co.jp


Sponsor or person

Institute

IMEQRD Co. Ltd.

Institute

Department

Personal name



Funding Source

Organization

AUREO Co. Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Suda Clinic institutional review board

Address

2-8-14, Takadanobaba, Shinjyuku, Tokyo

Tel

03-6704-5968

Email

jimukyoku@imeqrd.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 07 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 06 Month 16 Day

Date of IRB


Anticipated trial start date

2026 Year 09 Month 07 Day

Last follow-up date

2026 Year 11 Month 02 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 07 Month 06 Day

Last modified on

2026 Year 07 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071065